Navigation Links
ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc.
Date:4/9/2008

zed cases of transmission of vCJD by transfusion of blood donated by persons incubating the disease. Transfusion transmission appears to be highly efficient in humans and animals. The 2006 National CJD Surveillance Unit report concluded that "the incidence of vCJD may increase again, particularly if different genetic subgroups are found but with longer incubation periods". Abnormal prion proteins are an essential component of vCJD infectivity and may be the only component. The adsorption of prion proteins by PRDT ligands removes vCJD infectivity.

For additional information please refer to the following articles:

------------------------------------------------------------------

Gregori L, Lambert BC, Gurgel P et al. Reduction of transmissible spongiform encephalopathy infectivity from human red blood cells with prion protein affinity ligand. Transfusion 2006; 46:1152-1161

Wroe SJ, Pal S, Siddique D, et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion : a case report. Lancet 2006; 368:2061-67

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. ("ProMetic") (http://www.prometic.com) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand(TM) technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing
'/>"/>

SOURCE PROMETIC LIFE SCIENCES INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Prometic to present at the American Chemical Society
2. ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia
3. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
4. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
5. ProMetic provides business update - Over $35 million worth of business secured in January
6. ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use
7. ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies
8. PerOs obtains USDA Establishment and Product Licenses for its oral vaccine formulations
9. China Kangtai Cactus Biotech, Inc. Obtains $500,000 Equity Financing
10. NEXCORE Technology Obtains Licenses for Revolutionary Fluid Management System
11. Genelex Corporation Defends Consumers Right to Obtain DNA Information:
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... NY (PRWEB) May 17, 2013 ... Topical BioMedics, Inc., has been listed among nationally ... in an initiative conducted by "U.S. News" Health ... has earned the “No. 1 Pharmacists Recommended ... 17 other national OTC brands, and is the ...
(Date:5/17/2013)... is available in German . ... with the naked eye, you can see which branch a ... blur of branches through the telephoto lens for high-magnification images ... who are looking to study proteins, the active biomolecules of ... Institute for Molecular Systems Biology, and her colleagues have now ...
(Date:5/17/2013)... PHILADELPHIA , May 17, 2013 ... held by the most innovative thought leaders of ... Device & Manufacturing East conference and expo, from ...      (Photo: http://photos.prnewswire.com/prnh/20130517/613829 ) ... were designed to deliver industry professionals practical presentations ...
(Date:5/17/2013)... , May 17, 2013  Insero Health, Inc., ... needs in epilepsy and related neurological disorders, is today ... its lead compound INS001 in patients with drug-resistant epilepsy.  ... and Device Trials (AED) Xll meeting by Dr. ... and Chairman of Insero,s Scientific Advisory Board.  In this ...
Breaking Biology Technology:Pharmacists' Picks: Topical BioMedics' Topricin Listed on Top Recommended OTC Health Products 2Proteome atlas for the tuberculosis pathogen 2Proteome atlas for the tuberculosis pathogen 3MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2
... , KALAMAZOO, Mich., Nov. 3 Tolera Therapeutics, Inc., ... application with the United States Food and Drug Administration ... acute rejection of solid organ transplantation. TOL101 is ... and specifically target T cells, components of the immune ...
... , SOUTH SAN FRANCISCO, Calif., Nov. 3 Poniard Pharmaceuticals, ... oncology, today reported financial results for the third quarter ended ... "During the third quarter, we reached the 320th event target ... picoplatin for the treatment of small cell lung cancer. ...
... November 3 The new market research,report, ,Global ... 2014),published by MarketsandMarkets ( http://www.marketsandmarkets.com ) analyzes,the major ... identifies and analyzes,the main market drivers, restraints, and ... submarkets in different,geographic regions. , ...
Cached Biology Technology:Tolera Therapeutics Files IND Application for TOL101, Appoints O'Toole to Lead Clinical Operations 2Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 2Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 3Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 4Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 5Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 6Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 7MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014 2MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014 3
(Date:5/16/2013)... a conservationist working in Cameroon and the manager of ... been awarded the prestigious Whitley award. The Whitley ... "The Green Oscars" because it celebrates the extraordinary achievements ... developing countries. Abwe was selected for the award ... Cameroon,s Ebo Forest and its wildlife inhabitants., HRH The ...
(Date:5/16/2013)... The consultancy Frost & Sullivan ... Germany,s largest biometrics manufacturer, DERMALOG ... DERMALOG has been honored yesterday night by ... the category Global Biometrics and Border Control  Customer Value ... Border Control System . One of the decisive factors ...
(Date:5/15/2013)... In the largest clinical trial to date to examine ... carriers with diseases other than breast and ovarian cancer, ... against advanced pancreatic and prostate cancers. Results of the ... Medicine at the University of Pennsylvania and Sheba Medical ... the American Society of Clinical Oncology,s annual meeting in ...
Breaking Biology News(10 mins):Cameroon researcher wins prestigious 'Green Oscar' 2Cameroon researcher wins prestigious 'Green Oscar' 3Global Biometrics and Border Control Award for DERMALOG 2Global Biometrics and Border Control Award for DERMALOG 3Global Biometrics and Border Control Award for DERMALOG 4PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations 2
... A new DNA-based prenatal blood test that can strikingly ... a pregnancy with Down syndrome is ready to be introduced ... as 10 weeks of pregnancy to women who have been ... are the results of an international, multicenter study published online ...
... BROOKLYN, NY October 17, 2011 The Peggy ... Scientific Officer and Senior Vice President of Optimer Pharmaceuticals, ... Medicine at Tufts University, with an achievement award to ... pursuit of new treatments for Clostridium difficile ...
... discovered that a gene known as an androgen receptor (AR) ... opposite effects on these diseases. In prostate cancer, the AR ... breast cancer, the AR gene promotes cancer growth when the gene ... AR production ceases in women. What this means is that ...
Cached Biology News:Study shows that new DNA test to identify Down syndrome in pregnancy is ready for clinical use 2Study shows that new DNA test to identify Down syndrome in pregnancy is ready for clinical use 3Peggy Lillis Foundation honors Dr. Sherwood Gorbach for career combating C. diff infection 2Peggy Lillis Foundation honors Dr. Sherwood Gorbach for career combating C. diff infection 3Researchers discover that same gene has opposite effects in prostate, breast cancers 2
... Anti-YAP Polyclonal Antibody ... purified rabbit polyclonal antibody. Detects 70 ... in Western blotting and immunohistochemistry. ... proliferation Storage: ...
Rabbit polyclonal to QKI...
Mouse polyclonal antibody to QPRT - quinolinate phosphoribosyltransferase (nicotinate-nucleotide pyrophosphorylase (carboxylating))...
... without ammonium sulfate are compatible with thermostable ... Taq and AmpliThem™™ DNA polymerases. You can ... in one experiment by adding your own ... PreMixes supplied with the kit. This capability ...
Biology Products: